Back to top

Image: Bigstock

United Therapeutics Corporation

Read MoreHide Full Article

United Therapeutics holds a strong position in the PAH market with four approved products targeting this indication. The company has many phase III programs in the fields of cardiopulmonary diseases and oncology. It is working on new delivery mechanisms for Remodulin and expanded indications for its other marketed products like Orenitram and Tyvaso, which might drive long-term growth. Several data read-outs and regulatory updates are expected in 2018. The latest deal to merge with SteadyMed will add SteadyMed’s drug device pipeline product Trevyent to its portfolio, which could have posed competition to RemoSynch. However, competition in the PAH market is increasing, which is a concern. We believe the company needs to use cash suitably to deal with potential generic competition for two of its biggest products - Remodulin and Adcirca - by mid-2018. United Therapeutics’ shares have also underperformed the industry this year so far.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

United Therapeutics Corporation (UTHR) - free report >>

Published in